Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PLSE |
---|---|---|
09:32 ET | 3910 | 7.8 |
09:39 ET | 450 | 7.77 |
09:43 ET | 3459 | 7.62 |
09:45 ET | 400 | 7.89 |
09:50 ET | 953 | 8 |
09:52 ET | 200 | 7.98 |
09:54 ET | 2900 | 8 |
09:56 ET | 400 | 8.09 |
09:57 ET | 300 | 8.09 |
09:59 ET | 300 | 8.09 |
10:03 ET | 975 | 8.04 |
10:08 ET | 2000 | 8.0179 |
10:14 ET | 100 | 8.045 |
10:15 ET | 200 | 8.08 |
10:28 ET | 5251 | 8.2 |
10:30 ET | 300 | 8.2 |
10:32 ET | 700 | 8.23 |
10:37 ET | 300 | 8.2 |
10:39 ET | 200 | 8.195 |
10:44 ET | 100 | 8.15 |
10:50 ET | 100 | 8.24 |
10:53 ET | 100 | 8.24 |
10:57 ET | 500 | 8.25 |
11:02 ET | 286 | 8.195 |
11:11 ET | 100 | 8.18 |
11:18 ET | 705 | 8.155 |
11:20 ET | 100 | 8.2 |
11:22 ET | 100 | 8.1501 |
11:27 ET | 100 | 8.19 |
11:31 ET | 100 | 8.18 |
11:33 ET | 100 | 8.21 |
11:36 ET | 100 | 8.25 |
11:44 ET | 2302 | 8.25 |
11:51 ET | 3618 | 8.34 |
11:54 ET | 200 | 8.29 |
11:56 ET | 100 | 8.29 |
11:58 ET | 1439 | 8.34 |
12:02 ET | 200 | 8.42 |
12:12 ET | 300 | 8.41 |
12:16 ET | 100 | 8.38 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Pulse Biosciences Inc | 431.3M | -10.3x | --- |
Heart Test Laboratories Inc | 457.0M | -13.0x | --- |
Cibus Inc | 456.7M | -1.0x | --- |
Nano-X Imaging Ltd | 566.3M | -9.2x | --- |
Orchestra Biomed Holdings Inc | 186.4M | -3.6x | --- |
MaxCyte Inc | 488.2M | -13.3x | --- |
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $431.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 55.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.65 |
EPS | $-0.82 |
Book Value | $0.80 |
P/E Ratio | -10.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.